Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of RCM and LC-OCT in Genodermatoses Associated with Skin Cancer: A Narrative Review.

Acta dermato-venereologica·2026
Same author

Value of reflectance confocal microscopy in guiding dermatological decision-making: insights from facial, body and oral lesion assessment.

Skin health and disease·2026
Same author

LC-OCT in differentiating lichen planus from discoid lupus erythematosus in challenging lesions.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Iontophoresis-Based Topical Drug Delivery for Dermatologic Conditions: A Systematic Review.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Applying RCM-Based Criteria to LC-OCT for Classifying Mucosal Melanoses: A Proof-of-Concept Study.

Dermatology practical & conceptual·2026
Same author

Unveiling the Importance of Early Detection of Oral Mucosal Melanoma with Non-Invasive Imaging Techniques.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Biologic therapies for psoriasis.

Catia de Felice1, Marco Ardigo, Enzo Berardesca

  • 1San Gallicano Dermatological Institute, 00144, Rome, Italy.

The Journal of Rheumatology. Supplement
|August 8, 2009
PubMed
Summary
This summary is machine-generated.

Psoriasis management is improving with new biologic therapies targeting tumor necrosis factor-alpha or T cells. These treatments offer effective, well-tolerated options for long-term remission and improved quality of life.

Related Experiment Videos

Last Updated: Jun 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

  • Dermatology and Immunology
  • Inflammatory Skin Diseases
  • Biologic Therapies

Background:

  • Psoriasis is a prevalent chronic inflammatory skin condition impacting patient quality of life and potentially causing disability.
  • Effective early management aims for safe, well-tolerated remission, addressing both skin and joint symptoms.

Purpose of the Study:

  • To review advances in psoriasis pathogenesis.
  • To discuss the development of targeted, effective, and well-tolerated long-term treatment options.
  • To highlight the role of novel biologic agents in improving patient quality of life.

Main Methods:

  • Review of recent advances in understanding psoriasis pathogenesis.
  • Analysis of targeted treatment options, specifically biologic agents.
  • Focus on therapies targeting tumor necrosis factor-alpha and T cells.

Main Results:

  • Novel biologic agents targeting specific pathways have been developed.
  • These agents demonstrate potential for effective and well-tolerated long-term administration.
  • Improved outcomes in both skin and joint manifestations are anticipated.

Conclusions:

  • Advances in understanding psoriasis pathogenesis have led to targeted biologic therapies.
  • Biologics targeting tumor necrosis factor-alpha (infliximab, etanercept, adalimumab) and T cells (efalizumab) offer improved management options.
  • These therapies promise enhanced quality of life for psoriasis patients through effective and safe long-term disease control.